TTrialPathMatch Me to Trials
← Back to trials
RecruitingCervical Cancer

A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients

Eligible age

18+ yrs

Accepts

Women

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

You may qualify if…

  • ✓ Female subjects age 18 years or older with diagnosis of advanced (stage IB1-IVA) HPV+ cervical cancer and have completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months.
  • ✓ Patients who are recommended to receive anto-PD-1 or anti-PD-L1 therapy after chemoradiation are eligible to enroll and can continue to receive such therapy while receiving study drug.
  • ✓ No history of or current evidence of residual disease or disease recurrence based on imaging and clinical assessments within 8 weeks of enrollment
  • ✓ HIV uninfected
  • ✓ Hepatitis B surface antigen negative
  • ✓ Anti-hepatitis C (HCV) antibody negative or negative HCV polymerase chain reaction (PCR)
  • ✓ Patients who are able and willing to comply with all study procedures and voluntarily sign an informed consent form
  • ✓ Adequate organ function as defined by the following parameters:

You may not qualify if…

  • ✕ Women of child-bearing potential (i.e., those who have had fertility-sparing procedures for the management of cervical cancer) will be excluded unless agreed to remain sexually abstinent or have a partner who is sterile (i.e. vasectomy), or use methods of contraception (e.g., oral contraception, barrier methods, spermicide, intrauterine device (IUD)), throughout the first 6 months of the study.
  • ✕ Because there is a risk for adverse events in nursing infants, breastfeeding must be discontinued if the mother is treated on study.
  • ✕ Diagnosed with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients diagnosed with acquired, hereditary, or congenital immunodeficiencies
  • ✕ Diagnosis with a medical condition that requires systemic treatment with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), alkylating agents, antimetabolites, radiation, Tumor Necrosis Factor (TNF) inhibitors, or systemic corticosteroids, either chronically or within 30 days of first PVX7 vaccination.
  • ✕ Administration of any blood product within 30 days of signing informed consent.
  • ✕ Need for ongoing therapeutic anticoagulation during the study period due to concern for increased risk of bleeding.
  • ✕ Previous severe allergic reaction or hypersensitivity to a vaccine or any of its components
  • ✕ Participation in a study with an investigational compound or device within 30 days of signing informed consent

Where it's recruiting

Alabama

Birmingham

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT06315257 · last updated 2026-07-01